MDL 101146 manufacturers
- MDL 101146
-
- $3400.00
-
2026-04-21
- CAS:149859-17-6
- Purity:
- Supply Ability: 10g
|
| | MDL 101146 Basic information |
| Product Name: | MDL 101146 | | Synonyms: | MDL 101146;L-Prolinamide, N-[4-(4-morpholinylcarbonyl)benzoyl]-L-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]- (9CI);MD 101;MDL 101;MDL-101;MD 101,146;146 | | CAS: | 149859-17-6 | | MF: | C29H37F5N4O6 | | MW: | 632.62 | | EINECS: | | | Product Categories: | | | Mol File: | 149859-17-6.mol |  |
| | MDL 101146 Chemical Properties |
| Boiling point | 778.751±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.300±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.640±0.20(predicted) |
| | MDL 101146 Usage And Synthesis |
| Uses | MDL 101146 is an orally active neutrophil elastase inhibitor. MDL 101146 inhibits neutrophil elastase for human with a Ki value of 25 nM. MDL 101146 can be used for the research of arthritis[1][2]. | | in vivo | MDL 101146 (oral, 200 mg/kg/day) significantly inhibits swelling and joint destruction in collagen-induced arthritis but not in adjuvant arthritis[2]. | Animal Model: | Rats[2] | | Dosage: | 200 mg/kg | | Administration: | Oral, 200 mg/kg/day | | Result: | Inhibited the severity of collagen-induced arthritis.
Had a bone and cartilage sparing effect in the tibio-tarsal joint of animals with collagen-induced arthritis.
|
| | References | [1] Angelastro M, et al. Inhibition of human neutrophil elastase with peptidyl DOI:10.1021/jm00052a013
[2] M J Janusz, et al. Inhibition of cartilage degradation in rat collagen-induced arthritis but not adjuvant arthritis by the neutrophil elastase inhibitor MDL 101,146. Inflamm Res. 1997 Dec;46(12):503-8. DOI:10.1007/s000110050233 |
| | MDL 101146 Preparation Products And Raw materials |
|